Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Bexxar: encouraging interim phase III data reported

May 14, 1998

DAB389IL-7, a novel fusion protein for the specific elimination of IL-7 receptor-positive cells

May 12, 1998

Patient enrollment begins for U.S. trial of Maxamine in malignant melanoma

May 11, 1998

Multikine clinical trials update

May 11, 1998

Genentech files for marketing approval of Herceptin

May 5, 1998

Biomira initiates bridging study of Theratope cancer vaccine

May 4, 1998

Efficacy of StressGen's HspE7 in preclinical cancer models reported at FASEB 98

April 28, 1998

Cytokine Networks to initiate clinical trial of anticancer vaccine

April 24, 1998

Schering-Plough seeks FDA approval for Intron A combination

April 20, 1998

Mechanism of cytotoxic effect of ImmTher

April 9, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.